Ekttitab Holding Company K.S.C Past Earnings Performance
Past criteria checks 0/6
Ekttitab Holding Company K.S.C's earnings have been declining at an average annual rate of -10.6%, while the Capital Markets industry saw earnings growing at 15.8% annually. Revenues have been declining at an average rate of 65.9% per year.
Key information
-10.6%
Earnings growth rate
-10.6%
EPS growth rate
| Capital Markets Industry Growth | 24.8% |
| Revenue growth rate | -65.9% |
| Return on equity | -201.0% |
| Net Margin | 179.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ekttitab Holding Company K.S.C makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | -2 | -3 | 1 | 0 |
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -2 | 2 | 0 |
| 31 Mar 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 2 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | -1 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 30 Sep 19 | 0 | 0 | 1 | 0 |
| 30 Jun 19 | 0 | 0 | 1 | 0 |
| 31 Mar 19 | 0 | 0 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
| 30 Sep 18 | -1 | -1 | 1 | 0 |
| 30 Jun 18 | -1 | -2 | 1 | 0 |
| 31 Mar 18 | -1 | -2 | 1 | 0 |
| 31 Dec 17 | -1 | -1 | 1 | 0 |
| 30 Sep 17 | -1 | -1 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | -1 | -1 | 0 | 0 |
| 30 Sep 16 | -3 | -4 | 1 | 0 |
| 30 Jun 16 | -3 | -4 | 0 | 0 |
| 31 Mar 16 | -4 | -4 | 1 | 0 |
| 31 Dec 15 | -3 | -3 | 1 | 0 |
| 30 Sep 15 | -3 | -2 | 0 | 0 |
| 30 Jun 15 | -3 | -2 | 0 | 0 |
| 31 Mar 15 | -2 | -2 | 0 | 0 |
| 31 Dec 14 | -3 | -3 | 0 | 0 |
| 30 Sep 14 | -1 | -1 | 0 | 0 |
| 30 Jun 14 | -1 | -1 | 0 | 0 |
| 31 Mar 14 | -1 | -1 | 0 | 0 |
| 31 Dec 13 | -1 | -2 | 0 | 0 |
| 30 Sep 13 | -1 | -1 | 0 | 0 |
Quality Earnings: EKTTITAB is currently unprofitable.
Growing Profit Margin: EKTTITAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EKTTITAB is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare EKTTITAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EKTTITAB is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (46%).
Return on Equity
High ROE: EKTTITAB has a negative Return on Equity (-201.04%), as it is currently unprofitable.